Civetta Therapeutics was founded to advance new medicines through targeting of beta-propeller domains with the goal of developing important therapeutics for cancers and other serious diseases.
Propeller proteins are structural scaffolds that mediate interactions with proteins, nucleic acids and other biomolecules. These proteins are found ubiquitously across cell types and can have diverse functional roles in the pathogenesis of cancer, inflammation, neurodegeneration, metabolic disease and other diseases.
As the leader in beta-propeller science, our vision is to build a portfolio of therapeutics by integrating a broad range of expertise in spanning structural biology, genomics, biology and medicinal chemistry. These efforts support the continued advancement of our current therapeutic programs and evolution of our platform expertise in drugging beta propeller domains.